HBs seroconversion in a patient with acute hepatitis B treated with entecavir during immunosuppression against severe bronchiolitis obliterans in the course of chronic graft versus host disease

Journal of Clinical Virology

Volumn 48, Issue 3, 2010, Pages 218-219

  Christopeit, Maximilian ^a   Weber, Thomas ^a   Abendroth, Jens ^a   Dollinger, Matthias ^b   Lübbert, Christoph ^b   Oehme, Albrecht ^c   Kekulé, Alexander S ^c   Behre, Gerhard ^a  

^a Oncology and Hematology   (Germany)

^b Gastroenterology   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Allogeneic transplantation; Chronic graft versus host disease; Entecavir; Hepatitis B; Immunosuppression

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN; ENTECAVIR; FLUDARABINE; FOSCARNET; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; MYCOPHENOLIC ACID; PREDNISOLONE; TREOSULFAN;

ACUTE HEPATITIS; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANOREXIA; ANTIBODY TITER; ARTICLE; BRONCHIOLITIS OBLITERANS; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EXAMINATION; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; FATIGUE; FEMALE; GRAFT VERSUS HOST REACTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; MYELOFIBROSIS; OSTEOMYELOFIBROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROCONVERSION; SEROLOGY; TREATMENT RESPONSE; VIRUS REACTIVATION; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; BRONCHIOLITIS OBLITERANS; FEMALE; GRAFT VS HOST DISEASE; GUANINE; HEPATITIS B; HEPATITIS B ANTIBODIES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77953121262     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.03.009     Document Type: Article

References (8)

1. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113 14 (2009) 3147-3153
2. Liang R., Lau G.K., and Kwong Y.L. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17 1 (1999) 394-398
3. Sandherr M., Einsele H., Hebart H., Kahl C., Kern W., Kiehl M., et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 17 7 (2006) 1051-1059
4. Lalazar G., Rund D., and Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136 5 (2007) 699-712
5. Garcia-Rodriguez M.J., Canales M.A., Hernandez-Maraver D., and Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?. Am J Hematol 83 8 (2008) 673-675
6. Colson P., Borentain P., Coso D., Chabannon C., Tamalet C., and Gerolami R. Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 143 1 (2008) 148-150
7. Sanchez M.J., Buti M., Homs M., Palacios A., Rodriguez-Frias F., and Esteban R. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 51 6 (2009) 1091-1096
8. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50 2 (2009) 227-242